Alkermes releases transcript of Q2 2026 earnings call

• Alkermes discussed Q2 2026 results on an earnings call attended by CEO Richard Pops, CFO Joshua Reed, CCO Todd Nichols, COO and incoming CEO Blair Jackson.
• Pops said Blair Jackson becomes CEO next week; Alkermes will keep Pops as chairman.
• Management highlighted orexin portfolio momentum: phase 3 alixorexton narcolepsy studies enrolling, completion expected next year; Vibrance-3 idiopathic hypersomnia phase 2 completes in Q4.
• Blair Jackson said ALKS 7290 adult ADHD phase 1b topline data are expected by end-Q3; ALKS 4510 fatigue phase 2 planned later this year.
• Reed reported Q2 total revenue of $496 million; Q3 revenue guided to $450-$470 million, adjusted EBITDA to $80-$100 million; cash and investments about $690 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alkermes plc published the original content used to generate this news brief on July 28, 2026, and is solely responsible for the information contained therein.